コレステロール市場- 成長、将来展望、競合分析、2023～2031年

コレステロール市場は、業界情勢の形成に極めて重要な役割を果たしたいくつかの主要促進要因に牽引され、2023年から2031年の予測期間中にCAGR 7.7％を記録すると予測されています。コレステロール市場の成長は、心血管疾患の有病率の増加、予防ヘルスケアへの注目の高まり、医薬品開発の進歩といった要因に後押しされています。しかし、安全性への懸念や潜在的な副作用が、慎重な検討を必要とする複雑な阻害要因となっています。地域によって動向はさまざまであり、競合の動向は、業界の需要の変化に対応するための主要企業の戦略を浮き彫りにしています。2023年から2031年にかけて、コレステロール市場は、技術の進歩、医療パラダイムの変化、心血管の健康増進の必要性によって、継続的な成長が見込まれます。

心血管疾患の有病率の増加

心血管疾患の有病率の上昇は、コレステロール市場を促進する主要な要因となっています。コレステロール値、特に低比重リポ蛋白（LDL）コレステロール値の上昇は、心臓疾患の主要な危険因子であることが確認されています。この認識により、ヘルスケア専門家や患者の間で意識が高まり、コレステロールを低下させる介入療法への需要が高まっています。A社のような企業は、LDL コレステロール低下をターゲットとした革新的な治療法を開発し、心血管リスクを軽減する可能性から大きな注目を集めています。心血管疾患の大きな負担は、効果的なコレステロール管理の重要な必要性を浮き彫りにし、市場の成長に拍車をかけています。

予防ヘルスケアへの注目の高まり

予防ヘルスケアへのシフトが、コレステロール管理ソリューションの需要を高めています。慢性疾患の発症を予防するため、個人が積極的に健康管理を行うようになってきています。このような積極的なアプローチにより、定期的な健康診断の一環としてコレステロールのスクリーニングと管理が採用されるようになっています。さらに、ヘルスケアプロバイダーは、コレステロール値をコントロールするために、ライフスタイルの改善や食事介入を重視しています。食事カウンセリング、運動推奨、コレステロール低下薬を含むB社の包括的アプローチは、予防ヘルスケア戦略の重視の高まりに対する業界の対応を例証するものです。

医薬品開発の進歩

医薬品開発の目覚ましい進歩は、コレステロール市場の拡大に大きく貢献しています。製薬会社はコレステロールの生合成、吸収、代謝をターゲットとした新しい治療法を発表しています。これらの治療法は、コレステロールレベルを効果的に管理するための多様な選択肢を患者に提供しています。特筆すべきは、C社が、コレステロール管理戦略を調整するために遺伝的洞察を活用する画期的な治療法を発表したことです。医薬品開発におけるこのような革新は、治療の展望を一変させ、個別化された効果的なコレステロール管理ソリューションを求める患者に有望な道を提供しています。

安全性への懸念と副作用

市場の成長にもかかわらず、コレステロール低下薬に関連する安全性への懸念や潜在的な副作用が大きな抑制要因として浮上しています。スタチンなどの特定のコレステロール低下薬は、筋肉痛、肝機能障害、糖尿病などの副作用と関連しています。このような懸念から、特に潜在的なベネフィットを潜在的なリスクと天秤にかけて、コレステロール降下療法を開始することをためらう患者や医療従事者もいます。コレステロール管理介入のベネフィットとリスクのバランスを取ることは、患者にとっても医療従事者にとっても複雑な課題です。

タイプ別市場セグメンテーション：LDLのコレステロール関連製品が市場を独占

コレステロール市場は、低比重リポタンパク質（LDL）コレステロール、高比重リポタンパク質（HDL）コレステロール、超低比重リポタンパク質（VLDL）コレステロールを含むタイプ別に区分することができます。2022年の売上高では、心血管リスクの評価と管理において極めて重要な役割を果たすLDL コレステロール関連製品が市場を席巻しました。しかし、2023年から2031年までの予測期間では、HDL コレステロール関連製品が最も高い年間平均成長率（CAGR）を示すと予想されます。HDL コレステロールの心血管系の健康に対する保護作用が認識され、HDLの機能性を標的とした革新的な治療法が開発されたことが、この予測成長を下支えしています。

供給源別の市場セグメンテーション：動物由来製品が市場を独占

市場セグメンテーションには、植物由来、動物由来、合成コレステロール関連製品が含まれます。2022年には、動物由来製品が最も高い売上比率を占めており、これはコレステロールを豊富に含む動物性食品源の普及と、研究や診断用途における動物由来コレステロールの確立された使用によるものです。一方、2023年から2031年の予測期間では、植物由来製品が最も高いCAGRを達成すると予想されます。健康と持続可能性への配慮から植物ベースの食生活の採用が増加していることが、植物由来コレステロール製品の予想成長に寄与しています。

北米が世界のリーダーであり続ける

地域別では、コレステロール市場は多様な動向を見せており、地域によって収益の貢献度や成長率が異なります。アジア太平洋地域は、2023年から2031年の予測期間中に最も高いCAGRを記録する見通しです。急速な都市化、食生活の変化、中国やインドなどのヘルスケア意識の高まりが、この地域の堅調な成長見通しを後押ししています。しかし、北米は、心血管疾患の有病率の高さ、洗練されたヘルスケアインフラ、予防医療への重点的な取り組みに起因して、2022年に最も高い売上比率を維持しました。

市場競争は予測期間中に激化へ

コレステロール市場では、複数の主要プレーヤーが業界のリーダーとして台頭しており、それぞれが競争上の足場を確保し市場シェアを拡大するために独自の戦略を採用しています。これらの戦略には、研究開発投資、戦略的提携、市場拡大、患者中心のアプローチなどが含まれます。Chongqing Jingkang Biotechnology Co., Ltd.、CARBOGEN AMCIS、Zhejiang Garden Biochemical High-Tech Stock Co.Ltd.、Avanti Polar Lipids, Inc.、Anhui Chem-Bright Bioengineering Co.Ltd.、Rocky Mountain Biologicals、Lee BioSolutions, Inc.、Cone Bioproducts、Beckman Coulter、Alfa Wassermann Diagnostic Technologies, LLCなどの大手企業は、革新的なコレステロール管理ソリューションを提供する能力によって、2022年に堅調な財務実績を示しています。これらの企業は、2023年から2031年にかけて成長を維持するために、科学的専門知識を活用し、治療法の提供を強化し、新たな機会を活用することが期待されます。予測期間には、多様な患者のニーズに対応する包括的なコレステロール管理戦略を開発するために、製薬企業、研究機関、ヘルスケアプロバイダー間の共同研究が増加すると予想されます。

目次

第1章 序文

• レポート内容
  • 報告書の目的
  • 対象者
  • 主な提供商品
• 市場セグメンテーション
• 調査手法
  • フェーズⅠ-二次調査
  • フェーズⅡ-一次調査
  • フェーズⅢ-有識者レビュー
  • 前提条件
  • 採用したアプローチ

第2章 エグゼクティブサマリー

第3章 コレステロール市場：競合分析

• 主要ベンダーの市場での位置付け
• ベンダーが採用する戦略
• 主要な産業戦略
• ティア分析：2022 vs 2031

第4章 コレステロール市場：マクロ分析と市場力学

• イントロダクション
• 世界のコレステロール市場金額 2021-2031
• 市場力学
  • 市場促進要因
  • 市場抑制要因
  • 主な課題
  • 主な機会
• 促進要因と抑制要因の影響分析
• シーソー分析

第5章 コレステロール市場：タイプ別 2021-2031

• 市場概要
• 成長・収益分析：2022 vs 2031
• 市場セグメンテーション
  • 低密度リポタンパク質（LDL）
  • 高密度リポタンパク質（HDL）
  • 超低密度リポタンパク質（VLDL）

第6章 コレステロール市場：ソース別 2021-2031

• 市場概要
• 成長・収益分析：2022 vs 2031
• 市場セグメンテーション
  • 植物由来
  • 動物由来
  • 合成

第7章 コレステロール市場：最終用途別 2021-2031

• 市場概要
• 成長・収益分析：2022 vs 2031
• 市場セグメンテーション
  • 医薬品
  • 化粧品
  • 飲食品
  • 動物の飼料
  • 工業製品
  • その他

第8章 北米のコレステロール市場 2021-2031

• 市場概要
• コレステロール市場：タイプ別 2021-2031
• コレステロール市場：ソース別 2021-2031
• コレステロール市場：最終用途別 2021-2031
• コレステロール市場：地域別 2021-2031
  • 北米
    • 米国
    • カナダ
    • その他北米地域

第9章 英国と欧州連合のコレステロール市場 2021-2031

• 市場概要
• コレステロール市場：タイプ別 2021-2031
• コレステロール市場：ソース別 2021-2031
• コレステロール市場：最終用途別 2021-2031
• コレステロール市場：地域別 2021-2031
  • 英国と欧州連合
    • 英国
    • ドイツ
    • スペイン
    • イタリア
    • フランス
    • その他欧州地域

第10章 アジア太平洋のコレステロール市場 2021-2031

• 市場概要
• コレステロール市場：タイプ別 2021-2031
• コレステロール市場：ソース別 2021-2031
• コレステロール市場：最終用途別 2021-2031
• コレステロール市場：地域別 2021-2031
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域

第11章 ラテンアメリカのコレステロール市場 2021-2031

• 市場概要
• コレステロール市場：タイプ別 2021-2031
• コレステロール市場：ソース別 2021-2031
• コレステロール市場：最終用途別 2021-2031
• コレステロール市場：地域別 2021-2031
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ地域

第12章 中東・アフリカのコレステロール市場 2021-2031

• 市場概要
• コレステロール市場：タイプ別 2021-2031
• コレステロール市場：ソース別 2021-2031
• コレステロール市場：最終用途別 2021-2031
• コレステロール市場：地域別 2021-2031
  • 中東・アフリカ
    • GCC
    • アフリカ
    • その他中東・アフリカ地域

第13章 企業プロファイル

• Chongqing Jingkang Biotechnology Co. Ltd.
• CARBOGEN AMCIS
• Zhejiang Garden Biochemical High-Tech Stock Co. Ltd
• Avanti Polar Lipids Inc.
• Anhui Chem-Bright Bioengineering Co. Ltd.
• Rocky Mountain Biologicals
• Lee BioSolutions Inc.
• Cone Bioproducts
• Beckman Coulter
• Alfa Wassermann Diagnostic Technologies LLC
• その他の主要企業

List of Tables

• TABLE 1 Global Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 2 Global Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 3 Global Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 4 North America Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 5 North America Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 6 North America Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 7 U.S. Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 8 U.S. Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 9 U.S. Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 10 Canada Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 11 Canada Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 12 Canada Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 13 Rest of North America Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 14 Rest of North America Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 15 Rest of North America Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 16 UK and European Union Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 17 UK and European Union Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 18 UK and European Union Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 19 UK Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 20 UK Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 21 UK Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 22 Germany Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 23 Germany Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 24 Germany Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 25 Spain Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 26 Spain Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 27 Spain Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 28 Italy Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 29 Italy Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 30 Italy Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 31 France Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 32 France Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 33 France Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 34 Rest of Europe Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 35 Rest of Europe Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 36 Rest of Europe Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 37 Asia Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 38 Asia Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 39 Asia Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 40 China Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 41 China Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 42 China Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 43 Japan Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 44 Japan Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 45 Japan Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 46 India Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 47 India Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 48 India Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 49 Australia Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 50 Australia Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 51 Australia Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 52 South Korea Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 53 South Korea Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 54 South Korea Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 55 Latin America Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 56 Latin America Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 57 Latin America Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 58 Brazil Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 59 Brazil Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 60 Brazil Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 61 Mexico Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 62 Mexico Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 63 Mexico Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 64 Rest of Latin America Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 65 Rest of Latin America Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 66 Rest of Latin America Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 67 Middle East and Africa Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 68 Middle East and Africa Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 69 Middle East and Africa Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 70 GCC Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 71 GCC Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 72 GCC Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 73 Africa Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 74 Africa Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 75 Africa Cholesterol Market By End-use, 2021-2031, USD (Million)
• TABLE 76 Rest of Middle East and Africa Cholesterol Market By Type, 2021-2031, USD (Million)
• TABLE 77 Rest of Middle East and Africa Cholesterol Market By Source, 2021-2031, USD (Million)
• TABLE 78 Rest of Middle East and Africa Cholesterol Market By End-use, 2021-2031, USD (Million)

List of Figures

• FIG. 1 Global Cholesterol Market: Market Coverage
• FIG. 2 Research Methodology and Data Sources
• FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
• FIG. 4 Global Cholesterol Market: Quality Assurance
• FIG. 5 Global Cholesterol Market, By Type, 2022
• FIG. 6 Global Cholesterol Market, By Source, 2022
• FIG. 7 Global Cholesterol Market, By End-use, 2022
• FIG. 8 Global Cholesterol Market, By Geography, 2022
• FIG. 9 Market Geographical Opportunity Matrix - Global Cholesterol Market, 2022

FIG. 10Market Positioning of Key Cholesterol Market Players, 2022

FIG. 11Global Cholesterol Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

• FIG. 12 Global Cholesterol Market, By Type, 2022 Vs 2031, %
• FIG. 13 Global Cholesterol Market, By Source, 2022 Vs 2031, %
• FIG. 14 Global Cholesterol Market, By End-use, 2022 Vs 2031, %
• FIG. 15 U.S. Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 16 Canada Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 17 Rest of North America Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 18 UK Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 19 Germany Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 20 Spain Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 21 Italy Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 22 France Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 23 Rest of Europe Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 24 China Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 25 Japan Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 26 India Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 27 Australia Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 28 South Korea Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 29 Rest of Asia Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 30 Brazil Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 31 Mexico Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 32 Rest of Latin America Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 33 GCC Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 34 Africa Cholesterol Market (US$ Million), 2021 - 2031
• FIG. 35 Rest of Middle East and Africa Cholesterol Market (US$ Million), 2021 - 2031

The cholesterol market is expected to experience a CAGR of 7.7% during the forecast period of 2023 to 2031, driven by several key drivers that have played a pivotal role in shaping the industry landscape. The cholesterol market's growth is fueled by drivers such as the increasing prevalence of cardiovascular diseases, the growing focus on preventive healthcare, and advancements in drug development. Yet, safety concerns and potential side effects have introduced a complex restraint that necessitates careful consideration. Geographically, regions present varying trends, while competitive dynamics underscore key players' strategies to navigate evolving industry demands. As the market progresses from 2023 to 2031, the cholesterol market is positioned for continued growth, driven by technological advancements, shifting healthcare paradigms, and the imperative to improve cardiovascular health.

Increasing Prevalence of Cardiovascular Diseases

The escalating prevalence of cardiovascular diseases has been a major driver propelling the cholesterol market. Elevated cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol, have been identified as a major risk factor for heart diseases. This recognition has led to heightened awareness among healthcare professionals and patients alike, driving the demand for cholesterol-lowering interventions. Companies like Company A have developed innovative therapies targeting LDL cholesterol reduction, which have garnered significant attention due to their potential to mitigate cardiovascular risks. The substantial burden of cardiovascular diseases has underscored the critical need for effective cholesterol management, thereby fueling market growth.

Growing Focus on Preventive Healthcare

The shift towards preventive healthcare practices has bolstered the demand for cholesterol management solutions. Individuals are becoming increasingly proactive in managing their health to prevent the onset of chronic conditions. This proactive approach has driven the adoption of cholesterol screening and management as part of routine healthcare check-ups. Moreover, healthcare providers are emphasizing lifestyle modifications and dietary interventions to control cholesterol levels. Company B's comprehensive approach, encompassing dietary counseling, exercise recommendations, and cholesterol-lowering medications, exemplifies the industry's response to the growing emphasis on preventive healthcare strategies.

Advancements in Drug Development

Remarkable advancements in drug development have significantly contributed to the cholesterol market's expansion. Pharmaceutical companies have introduced novel therapies that target cholesterol biosynthesis, absorption, and metabolism. These therapies offer patients diverse options to effectively manage cholesterol levels. Notably, Company C has unveiled groundbreaking treatments that harness the power of genetic insights to tailor cholesterol management strategies. Such innovations in drug development have transformed the treatment landscape, offering promising avenues for patients seeking personalized and effective cholesterol management solutions.

Safety Concerns and Side Effects

Despite the market's growth, safety concerns and potential side effects associated with cholesterol-lowering medications have emerged as significant restraints. Certain cholesterol-lowering drugs, such as statins, have been associated with adverse effects like muscle pain, liver dysfunction, and diabetes. These concerns have led to hesitancy among some patients and healthcare providers to initiate cholesterol-lowering therapies, particularly in cases where the potential benefits are weighed against potential risks. Striking a balance between the benefits and risks of cholesterol management interventions remains a complex challenge for both patients and healthcare professionals.

Market Segmentation by Type: LDL Cholesterol-Related Products Dominate the Market

The cholesterol market can be segmented by type, encompassing low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and very-low-density lipoprotein (VLDL) cholesterol. In terms of revenue in 2022, LDL cholesterol-related products dominated the market, given their pivotal role in cardiovascular risk assessment and management. However, during the forecast period from 2023 to 2031, HDL cholesterol-related products are expected to exhibit the highest Compound Annual Growth Rate (CAGR). The recognition of HDL cholesterol's protective effects on cardiovascular health and the development of innovative therapies targeting HDL functionality underpin this projected growth.

Market Segmentation by Source: Animal-Derived Products Dominate the Market

Market segmentation by source includes plant-derived, animal-derived, and synthetic cholesterol-related products. In 2022, animal-derived products represented the highest revenue percentage, driven by the prevalence of cholesterol-rich animal-based food sources and the established use of animal-derived cholesterol in research and diagnostic applications. Meanwhile, during the forecast period of 2023 to 2031, plant-derived products are expected to achieve the highest CAGR. The increasing adoption of plant-based diets, driven by health and sustainability considerations, contributes to the anticipated growth of plant-derived cholesterol products.

North America Remains as the Global Leader

Geographically, the cholesterol market showcases diverse trends, with varying revenue contributions and growth rates across regions. The Asia-Pacific region is poised to register the highest CAGR during the forecast period of 2023 to 2031. Rapid urbanization, changing dietary patterns, and increasing healthcare awareness in countries like China and India drive the region's robust growth prospects. However, North America maintained the highest revenue percentage in 2022, attributed to the high prevalence of cardiovascular diseases, sophisticated healthcare infrastructure, and a strong focus on preventive healthcare practices.

Market Competition to Intensify during the Forecast Period

Within the cholesterol market, several key players have emerged as industry leaders, each employing distinct strategies to secure their competitive foothold and expand market share. These strategies encompass research and development investments, strategic partnerships, market expansion, and patient-centric approaches. Leading companies such as Chongqing Jingkang Biotechnology Co., Ltd. CARBOGEN AMCIS, Zhejiang Garden Biochemical High-Tech Stock Co., Ltd, Avanti Polar Lipids, Inc., Anhui Chem-Bright Bioengineering Co., Ltd., Rocky Mountain Biologicals, Lee BioSolutions, Inc., Cone Bioproducts, Beckman Coulter, Alfa Wassermann Diagnostic Technologies, LLC, have exhibited robust financial performance in 2022, driven by their ability to offer innovative cholesterol management solutions. These players are expected to leverage their scientific expertise, enhance therapeutic offerings, and capitalize on emerging opportunities to maintain growth from 2023 to 2031. The forecast period is anticipated to witness increased collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop comprehensive cholesterol management strategies that cater to diverse patient needs.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofCholesterol market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Cholesterol market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

Low-density Lipoprotein (LDL)

High-density Lipoprotein (HDL)

Very-low-density Lipoprotein (VLDL)

Source

Plant-derived

Animal-derived

Synthetic

End-use

Pharmaceutical

Cosmetics

Food & Beverage

Animal Feed

Industrial Products

Others

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Cholesterol market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Cholesterol market?

Which is the largest regional market for Cholesterol market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Cholesterol market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Cholesterol market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Cholesterol Market
• 2.2. Global Cholesterol Market, By Type, 2022 (US$ Million)
• 2.3. Global Cholesterol Market, By Source, 2022 (US$ Million)
• 2.4. Global Cholesterol Market, By End-use, 2022 (US$ Million)
• 2.5. Global Cholesterol Market, By Geography, 2022 (US$ Million)
• 2.6. Attractive Investment Proposition by Geography, 2022

3. Cholesterol Market: Competitive Analysis

• 3.1. Market Positioning of Key Cholesterol Market Vendors
• 3.2. Strategies Adopted by Cholesterol Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2022 Versus 2031

4. Cholesterol Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Cholesterol Market Value, 2021 - 2031, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Cholesterol Market: By Type, 2021-2031, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2022 Versus 2031
• 5.3. Market Segmentation
  • 5.3.1. Low-density Lipoprotein (LDL)
  • 5.3.2. High-density Lipoprotein (HDL)
  • 5.3.3. Very-low-density Lipoprotein (VLDL)

6. Cholesterol Market: By Source, 2021-2031, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2022 Versus 2031
• 6.3. Market Segmentation
  • 6.3.1. Plant-derived
  • 6.3.2. Animal-derived
  • 6.3.3. Synthetic

7. Cholesterol Market: By End-use, 2021-2031, USD (Million)

• 7.1. Market Overview
• 7.2. Growth & Revenue Analysis: 2022 Versus 2031
• 7.3. Market Segmentation
  • 7.3.1. Pharmaceutical
  • 7.3.2. Cosmetics
  • 7.3.3. Food & Beverage
  • 7.3.4. Animal Feed
  • 7.3.5. Industrial Products
  • 7.3.6. Others

8. North America Cholesterol Market, 2021-2031, USD (Million)

• 8.1. Market Overview
• 8.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 8.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 8.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 8.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 8.5.1.North America
    • 8.5.1.1. U.S.
      • 8.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 8.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 8.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 8.5.1.2. Canada
      • 8.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 8.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 8.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 8.5.1.3. Rest of North America
      • 8.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 8.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 8.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

9. UK and European Union Cholesterol Market, 2021-2031, USD (Million)

• 9.1. Market Overview
• 9.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 9.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 9.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 9.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 9.5.1.UK and European Union
    • 9.5.1.1. UK
      • 9.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.2. Germany
      • 9.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.3. Spain
      • 9.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.4. Italy
      • 9.5.1.4.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.4.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.4.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.5. France
      • 9.5.1.5.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.5.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.5.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 9.5.1.6. Rest of Europe
      • 9.5.1.6.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 9.5.1.6.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 9.5.1.6.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

10. Asia Pacific Cholesterol Market, 2021-2031, USD (Million)

• 10.1. Market Overview
• 10.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 10.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 10.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 10.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 10.5.1.Asia Pacific
    • 10.5.1.1. China
      • 10.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.2. Japan
      • 10.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.3. India
      • 10.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.4. Australia
      • 10.5.1.4.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.4.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.4.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.5. South Korea
      • 10.5.1.5.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.5.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.5.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 10.5.1.6. Rest of Asia Pacific
      • 10.5.1.6.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 10.5.1.6.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 10.5.1.6.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

11. Latin America Cholesterol Market, 2021-2031, USD (Million)

• 11.1. Market Overview
• 11.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 11.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 11.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 11.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 11.5.1.Latin America
    • 11.5.1.1. Brazil
      • 11.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 11.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 11.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 11.5.1.2. Mexico
      • 11.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 11.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 11.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 11.5.1.3. Rest of Latin America
      • 11.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 11.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 11.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

12. Middle East and Africa Cholesterol Market, 2021-2031, USD (Million)

• 12.1. Market Overview
• 12.2. Cholesterol Market: By Type, 2021-2031, USD (Million)
• 12.3. Cholesterol Market: By Source, 2021-2031, USD (Million)
• 12.4. Cholesterol Market: By End-use, 2021-2031, USD (Million)
• 12.5.Cholesterol Market: By Region, 2021-2031, USD (Million)
  • 12.5.1.Middle East and Africa
    • 12.5.1.1. GCC
      • 12.5.1.1.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 12.5.1.1.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 12.5.1.1.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 12.5.1.2. Africa
      • 12.5.1.2.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 12.5.1.2.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 12.5.1.2.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)
    • 12.5.1.3. Rest of Middle East and Africa
      • 12.5.1.3.1. Cholesterol Market: By Type, 2021-2031, USD (Million)
      • 12.5.1.3.2. Cholesterol Market: By Source, 2021-2031, USD (Million)
      • 12.5.1.3.3. Cholesterol Market: By End-use, 2021-2031, USD (Million)

13. Company Profile

• 13.1. Chongqing Jingkang Biotechnology Co., Ltd.
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Portfolio
  • 13.1.4. Strategic Initiatives
• 13.2. CARBOGEN AMCIS
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Portfolio
  • 13.2.4. Strategic Initiatives
• 13.3. Zhejiang Garden Biochemical High-Tech Stock Co., Ltd
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Portfolio
  • 13.3.4. Strategic Initiatives
• 13.4. Avanti Polar Lipids, Inc.
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Portfolio
  • 13.4.4. Strategic Initiatives
• 13.5. Anhui Chem-Bright Bioengineering Co., Ltd.
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Portfolio
  • 13.5.4. Strategic Initiatives
• 13.6. Rocky Mountain Biologicals
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Portfolio
  • 13.6.4. Strategic Initiatives
• 13.7. Lee BioSolutions, Inc.
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Portfolio
  • 13.7.4. Strategic Initiatives
• 13.8. Cone Bioproducts
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Portfolio
  • 13.8.4. Strategic Initiatives
• 13.9. Beckman Coulter
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Portfolio
  • 13.9.4. Strategic Initiatives
• 13.10. Alfa Wassermann Diagnostic Technologies, LLC
  • 13.10.1. Company Overview
  • 13.10.2. Financial Performance
  • 13.10.3. Product Portfolio
  • 13.10.4. Strategic Initiatives
• 13.11. Other Notable Players
  • 13.11.1. Company Overview
  • 13.11.2. Financial Performance
  • 13.11.3. Product Portfolio
  • 13.11.4. Strategic Initiatives